Jump Financial LLC Takes $1.31 Million Position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Jump Financial LLC bought a new position in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 165,916 shares of the company's stock, valued at approximately $1,314,000. Jump Financial LLC owned 0.05% of Amneal Pharmaceuticals at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in AMRX. Vanguard Group Inc. lifted its stake in shares of Amneal Pharmaceuticals by 1.5% during the 4th quarter. Vanguard Group Inc. now owns 14,841,969 shares of the company's stock valued at $117,548,000 after buying an additional 218,025 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Amneal Pharmaceuticals by 0.7% in the fourth quarter. Geode Capital Management LLC now owns 3,813,207 shares of the company's stock valued at $30,207,000 after acquiring an additional 26,536 shares in the last quarter. State Street Corp grew its position in shares of Amneal Pharmaceuticals by 3.8% during the third quarter. State Street Corp now owns 3,514,721 shares of the company's stock worth $29,242,000 after purchasing an additional 127,753 shares in the last quarter. Hennessy Advisors Inc. raised its stake in Amneal Pharmaceuticals by 6.8% during the 4th quarter. Hennessy Advisors Inc. now owns 1,670,600 shares of the company's stock valued at $13,231,000 after purchasing an additional 106,600 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its holdings in Amneal Pharmaceuticals by 9.6% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,539,934 shares of the company's stock worth $12,196,000 after purchasing an additional 135,051 shares in the last quarter. Hedge funds and other institutional investors own 31.82% of the company's stock.

Insider Activity at Amneal Pharmaceuticals

In related news, Director Gautam Patel sold 80,000 shares of the stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $8.90, for a total value of $712,000.00. Following the transaction, the director now owns 1,808,886 shares of the company's stock, valued at $16,099,085.40. This represents a 4.24 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Tushar Bhikhubhai Patel sold 5,000,000 shares of Amneal Pharmaceuticals stock in a transaction on Friday, March 14th. The shares were sold at an average price of $8.35, for a total value of $41,750,000.00. Following the sale, the insider now directly owns 48,578,209 shares of the company's stock, valued at approximately $405,628,045.15. This trade represents a 9.33 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 5,160,000 shares of company stock worth $43,113,200 in the last quarter. 17.45% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on AMRX. JPMorgan Chase & Co. upgraded shares of Amneal Pharmaceuticals from a "neutral" rating to an "overweight" rating and lifted their price objective for the company from $9.00 to $12.00 in a research report on Monday, February 24th. Barclays increased their target price on Amneal Pharmaceuticals from $10.00 to $11.00 and gave the company an "overweight" rating in a research report on Monday, March 3rd. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of "Buy" and an average price target of $10.80.

Amneal Pharmaceuticals Trading Up 1.7 %

Shares of NASDAQ AMRX traded up $0.13 during trading hours on Thursday, hitting $7.43. 746,259 shares of the company traded hands, compared to its average volume of 1,409,573. The company's 50 day moving average price is $8.07 and its 200 day moving average price is $8.21. Amneal Pharmaceuticals, Inc. has a 12 month low of $5.56 and a 12 month high of $9.48. The stock has a market capitalization of $2.30 billion, a price-to-earnings ratio of -10.92 and a beta of 1.06.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last released its earnings results on Friday, February 28th. The company reported $0.12 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.15 by ($0.03). Amneal Pharmaceuticals had a negative return on equity of 346.26% and a negative net margin of 6.88%. The firm had revenue of $730.52 million during the quarter, compared to the consensus estimate of $708.21 million. During the same quarter last year, the business posted $0.14 EPS. Equities analysts anticipate that Amneal Pharmaceuticals, Inc. will post 0.53 EPS for the current year.

Amneal Pharmaceuticals Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.